Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medical economics"
DOI: 10.1080/13696998.2022.2042106
Abstract: AIMS To conduct a cost-effectiveness analysis (CEA) on the use of andexanet alfa for the treatment of factor Xa inhibitor-related intracranial hemorrhage (ICH) from the United States (US) third-party payer and societal perspectives. METHODS CEA… read more here.
Keywords: cost; treatment; factor inhibitor; factor ... See more keywords
Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Cardiovascular Electrophysiology"
DOI: 10.1111/jce.15801
Abstract: Pericardial bleeding is a rare but lifeâthreatening complication of atrial fibrillation (AF) ablation. Patients taking uninterrupted oral anticoagulation (AC) may be at increased risk for refractory bleeding despite pericardiocentesis and administration of protamine. In such… read more here.
Keywords: refractory pericardial; ablation; pericardial bleeding; atrial fibrillation ... See more keywords
Preclinical safety and efficacy of andexanet alfa in animal models
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.13768
Abstract: Essentials There is currently no approved reversal agent for factor Xa (FXa) inhibitors Andexanet alfa has been developed to reverse the anticoagulant effects of FXa inhibitors Andexanet reduced blood loss and anticoagulation markers in rivaroxabanâanticoagulated… read more here.
Keywords: alfa animal; efficacy andexanet; safety efficacy; preclinical safety ... See more keywords
Abstract P403: Healthcare Resource Utilization and Costs Associated With Oral Anticoagulant Reversal With Idarucizumab or Andexanet Alfa for Patients Hospitalized With Life-Threatening Bleeding Events
Sign Up to like & getrecommendations! Published in 2021 at "Stroke"
DOI: 10.1161/str.52.suppl_1.p403
Abstract: Introduction: This study compared healthcare resource utilization and costs associated with the use of idarucizumab for the reversal of dabigatran, and andexanet alfa for the reversal of rivaroxaba... read more here.
Keywords: reversal; costs associated; resource utilization; healthcare resource ... See more keywords
Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296221078842
Abstract: Direct oral factor Xa inhibitors (DXIs) are approved for use in adult patients with non-valvular heart disease for stroke prevention, and the treatment/prevention of venous thromboembolism (VTE). Recent pediatric clinical trials have demonstrated safety and… read more here.
Keywords: complex concentrates; survey; hematology; reversal ... See more keywords
Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296221099934
Abstract: Introduction Andexanet alfa (andexanet) is an approved antidote used to reverse the bleeding effects of Direct Oral Anticoagulant (Direct-Xa agents) agents because it reverses anti-Xa activity. Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs)… read more here.
Keywords: neutralization; act; andexanet; ufh lmwh ... See more keywords
Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296221110568
Abstract: Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors. Methods: This retrospective… read more here.
Keywords: costs healthcare; alfa; reversal; healthcare resource ... See more keywords
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000885
Abstract: As with any anticoagulant, factor Xa (FXa) inhibitors are associated with a risk of major bleeding. Andexanet alfa is a recombinant modified human FXa lacking enzymatic activity, developed for reversal of FXa inhibitor-induced anticoagulation. In… read more here.
Keywords: anticoagulation; reversal; alfa; andexanet alfa ... See more keywords
Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report
Sign Up to like & getrecommendations! Published in 2022 at "A&a Practice"
DOI: 10.1213/xaa.0000000000001636
Abstract: The management of patients on direct oral anticoagulants (DOACs) who require emergent cardiac surgery is slowly evolving. The introduction of andexanet alfa, a novel antidote for apixaban and rivaroxaban, added a specific reversal agent to… read more here.
Keywords: complex concentrate; apixaban; andexanet; reversal ... See more keywords
Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Sign Up to like & getrecommendations! Published in 2017 at "Drugs of today"
DOI: 10.1358/dot.2017.53.5.2630780
Abstract: Activated coagulation factor X (FXa) is a common target for classic and newer anticoagulants. Parenteral anticoagulants with an indirect inhibitory action on FXa (low-molecular-weight heparins) have a well-established clinical efficacy in the prophylaxis and therapy… read more here.
Keywords: fxa; anticoagulant therapies; reversal anticoagulant; alfa ... See more keywords